title: The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.
abstract: Epidemiological studies have assessed the association between Fc gamma receptor IIIA (FCGR3A) 158 V/F and the response to rituximab-based therapy in patients with non-Hodgkin lymphoma (NHL), but the findings have been inconsistent. We performed this meta-analysis to obtain a better assessment of this relationship. Electronic database searches were conducted for relevant studies. A pooled odds ratio (OR) with a 95 % confidence interval (95 % CI) was used to assess the strength of the association. Analyses of the subgroup and publication bias were conducted. A total of 10 studies involving 1050 patients were analyzed. In all the genetic models, no clear relationship was found between the FCGR3A 158 V/F polymorphism and the response to rituximab-based therapy in NHL patients. When categorized by ethnicity, Asian individuals with the FCGR3A 158 V/V allele (OR = 4.37; 95 % CI = 1.07-17.73; P = 0.039) or the non-F/(FV + VV) (OR = 2.50; 95 % CI = 1.04-5.98; P = 0.040) allele have a significantly higher complete response rate (CR) compared to FF individuals. No obvious heterogeneities were observed. In addition, no statistical evidence for a publication bias was found. Our study suggested that the FCGR3A 158 V/F polymorphism can predict the treatment response to rituximab-based chemotherapy in NHL patients, especially for Asian individuals.
authors.affiliation: Department of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang, China.|Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
authors.forename: Duo
authors.initials: D
authors.lastname: Liu
authors.affiliation: Department of Hematology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
authors.forename: Yuyang
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Department of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Donglin
authors.initials: D
authors.lastname: Sun
authors.affiliation: Department of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang, China.
authors.forename: Haiming
authors.initials: H
authors.lastname: Sun
authors.affiliation: Department of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang, China. jinyanhmu@126.com.
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
authors.affiliation: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. mdhappy2006@hotmail.com.
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D017452:Receptors, IgG / Q000235:genetics*; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000069283:Rituximab
keywords: FCGR3A; Meta-analysis; Non-Hodgkin’s lymphoma; Polymorphism; Rituximab